Trinity Biotech Plc Profit Margin

Trinity Biotech Plc (TRIB) currently reports a profit margin of -85.33% as of December 2025. That compares with -51.64% in the prior-year period — down 65.2% year over year. That is below the Healthcare sector average of 15.58%. Use the charts on this page to explore Trinity Biotech Plc's profit margin history and peer comparisons.

Trinity Biotech Plc's profit margin decreased from -51.64% to -85.33% — a 65.2% year-over-year decrease (period ending December 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Trinity Biotech Plc's profit margin of -85.33% is lower than the Healthcare sector average of 15.58%. That is roughly 647.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Trinity Biotech Plc's current -85.33% should be judged against Healthcare norms (sector average: 15.58%) and against TRIB's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -85.33%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 15.58%. From there, open related valuation or income-statement pages for Trinity Biotech Plc, and consider following TRIB for alerts when major investors trade the stock.